Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 40

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 40
---
 matters required to be discussed by Auditing Standard No. 1301, Communications with Audit Committees, as adopted by the Public Company Accounting Oversight Board (“PCAOB”). The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent registered public 36

accounting firm’s communications with the Audit Committee concerning independence and has discussed with the independent registered public accounting firm the accounting firm’s independence. Based on the foregoing, the Audit Committee has recommended to our Board that the audited financial statements be included in the Company’s Annual Report on Form 10 K for the fiscal year ended December 31, 2024. Tamara A. Favorito (Chair) John B. Bode Wendy Dixon, Ph.D. Corey Watton

| (1) | The material in this report is not “soliciting material,” is not deemed “filed” with the Commission and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. |

Compensation Committee The Compensation Committee is composed of four directors, Thomas D. Anderson, Douglas W. Calder, Alvin Shih, M.D. and Corey Watton. All members of our Compensation Committee are independent under the Nasdaq listing rules, including with respect to service on a compensation committee, and each is a non-employeemember of our Board as defined in Rule 16b 3 under the Exchange Act. Mr. Anderson is the chair of the Compensation Committee. Our Board has determined that the composition of the Compensation Committee satisfies the applicable independence requirements under, and the functioning of our Compensation Committee complies with, the applicable requirements of the Nasdaq listing rules and SEC rules and regulations. The principal duties and responsibilities of the Compensation Committee include:

| • |     | reviewing our overall compensation strategy and policies, establishing and approving, or, if it deems appropriate, recommending to the full Board for determination and approval, performance goals and objectives relevant to the compensation of our Chief Executive Officer, evaluating the performance of our Chief Executive Officer in light of those goals and objectives and setting, or recommending to the full Board for approval, the compensation of our Chief Executive Officer, including incentive based and equity based compensation, based on that evaluation; |

| • |     | setting, or recommending to the full Board for approval